Cell & Gene Therapy CDMOs

AGC (AGC Biologics & AGC Pharma Chemicals)

United States

AGC Biologics is a leading global CDMO providing contract development and manufacturing services for biologics, cell and gene therapies, and advanced modalities. With facilities in Seattle, Copenhagen, Heidelberg, Milan, Chiba, and Yokohama, AGC operates mammalian and microbial expression systems and offers end-to-end services from process development through commercial-scale manufacturing.

BioNTech

Germany

BioNTech SE is a global biotechnology company headquartered in Mainz, Germany, that develops and manufactures mRNA-based immunotherapies and vaccines. While primarily a pharmaceutical innovator, BioNTech operates extensive in-house GMP manufacturing capabilities for mRNA, antibodies, and cell therapies across multiple global sites. They pioneered the BioNTainer modular mRNA manufacturing solution. FDA-registered for API manufacture and analysis. Active in 10+ clinical trials across oncology and infectious disease.

Boehringer Ingelheim Biopharmaceuticals GmbH (BioXcellence)

Germany

Boehringer Ingelheim BioXcellence is the contract biopharmaceutical manufacturing arm of Boehringer Ingelheim, one of the world's largest pharmaceutical companies. BioXcellence offers end-to-end biologics CDMO services including mammalian cell culture, microbial fermentation, viral vector production, and aseptic fill/finish with extensive FDA, EMA, and PMDA regulatory approvals across multiple global facilities.

Boston Institute of Biotechnology (BIB)

United States

Boston Institute of Biotechnology (BIB) is a US-based full-service CDMO offering cGMP and non-GMP mammalian, microbial, gene therapy, and cell therapy services. The company features the world's first ultra-large bioreactor with 30,000L working volume capacity and provides end-to-end services from cell line development through commercial-scale cGMP manufacturing.

Catalent Pharma Solution

Argentina

Catalent is a leading global CDMO trusted by pharma, biotech, and self-care companies to accelerate the development, manufacturing, and delivery of products that improve lives. With a worldwide network of facilities, advanced technologies, and deep expertise, Catalent provides integrated end-to-end solutions spanning oral dose, biologics, specialty therapies, cell and gene therapy, and clinical supply. The company partners with innovators from early-stage design through commercial manufacturing.

IDT Biologika

Germany

IDT Biologika is a leading global biologics CDMO headquartered in Germany, specializing in end-to-end development and manufacture of viral vaccines, gene and immune therapeutics, and aseptic fill-finish of sterile injectables. Founded in 1921 with over a century of experience in vaccines, the company operates BSL-2 facilities and has completed over 200 development, clinical, and commercial projects. IDT Biologika is a subsidiary of SK bioscience.

JCR Pharmaceuticals

Japan

JCR Pharmaceuticals is a Japanese pharmaceutical company and CDMO founded in 1975, with nearly 50 years of experience in rare disease treatments and orphan drug production. Selected for Japan's Regenerative Medicine CDMO Subsidy Program in 2025, the company is expanding biomanufacturing infrastructure for cell, gene, and regenerative medicine therapies. JCR operates five production sites and has proprietary platforms including JUST-AAV for gene therapy and J-Brain Cargo for blood-brain barrier penetration.

Lonza

Switzerland

Lonza is a pioneer and world leader in the CDMO industry, founded in Switzerland in 1897. The company provides integrated development and manufacturing services across biologics, small molecules, cell and gene therapy, mRNA, and bioconjugates (ADCs/HPAPIs). With over 20,000 employees across five continents, Lonza serves the global pharmaceutical, biotech, and nutrition industries with end-to-end capabilities from early development to commercial-scale manufacturing.

Novartis Contract Manufacturing

Austria

Novartis Contract Manufacturing is the CDMO arm of Novartis, offering fully integrated end-to-end manufacturing solutions across biologics (mammalian up to 15,000L, microbial up to 13,000L), small molecules (API to fill & finish), cell & gene therapy (CAR-T, AAV, LV), xRNA/LNP/pDNA, and comprehensive fill & finish services. The operation spans multiple state-of-the-art facilities across Austria, Switzerland, Slovenia, Belgium, France, Singapore, and the United States, with 107 FDA inspections and 27 FEI registrations.

Pharmaron

China

Pharmaron is a premier life science CRO/CDMO providing comprehensive R&D and manufacturing services across the entire drug discovery to commercialization process. The company serves small molecules, biologics, ADCs, cell & gene therapies, and protein degraders. It offers laboratory services, chemistry/manufacturing/controls (CMC), clinical development, and biologics/CGT manufacturing. Pharmaron acquired a commercial API manufacturing facility in the UK and operates a gene therapy CDMO in Liverpool with a 20-year track record. The company has over 20 years of experience across 7+ facilities in the UK, US, and China.

Porton Advanced Solutions

China

Porton Advanced Solutions is a China-based CRO and CDMO specializing in Advanced Therapy Medicinal Products (ATMPs). They provide end-to-end services from cell banking, process and analytical method development, GMP production, to fill and finish. Their platforms include lentivirus (for CAR-T, TCR-T, CAR-NK), plasmid DNA (supercoiled, linear, LcDNA), mRNA and LNP encapsulation, AAV, and bacterial vectors. They have achieved 18 IND approvals across NMPA (13), FDA (4), and MedSafe (1), with 300+ GMP batches and 200+ GMP IITs batches produced.

ProBioGen AG

Germany

ProBioGen AG is a fully integrated CDMO headquartered in Berlin, Germany, specializing in the development and GMP manufacturing of biopharmaceuticals, viral vectors, and vaccines. The company offers cell line development, process development, GMP manufacturing up to 1000L bioreactors, and comprehensive analytical services. ProBioGen leverages proprietary technologies including GlymaxX (ADCC enhancement), DirectedLuck (transposase system), and CHO.RiGHT production systems.

Rentschler Biopharma

Germany

Rentschler Biopharma is a leading global CDMO focused exclusively on biopharmaceuticals, with over 50 years of industry experience. The company contributed to nearly 25% of FDA-approved biopharmaceuticals in 2023, has supported 180+ biotherapeutics, and serves 180+ clients worldwide. It is an independent family-owned company employing approximately 1,400 people.

Sumitomo Chemical Co., Ltd.

Japan

Sumitomo Chemical Co., Ltd. is a major Japanese chemical company whose Advanced Medical Solutions Sector provides CDMO services for small molecule APIs and intermediates, oligonucleotide production (including gRNA for genome editing), and regenerative medicine/cell therapies through its S-RACMO joint venture with Sumitomo Pharma. The company also operates large agrochemical, IT materials, and essential materials businesses.

Symbiosis Pharmaceutical Services

United Kingdom

Symbiosis Pharmaceutical Services is a world-class sterile fill-finish CDMO based in Stirling, UK, specializing in the GMP manufacture of liquid and lyophilized biological and small molecule drug products. The company serves clinical trial and commercial scale with FDA-inspected and MHRA-licensed facilities. Symbiosis has manufactured its first 10,000-vial commercial batch for a cancer immunotherapy currently in Phase III trials. The company handles a full range of biologics including ATMPs, viral vectors, mAbs, ADCs, RNA/peptide therapies, and vaccines.

Thermo Fisher Scientific Inc.

China

One of the world's largest pharmaceutical CDMOs through its Patheon pharma services division. Provides end-to-end pharmaceutical development and manufacturing services for both small molecules and biologics, from API manufacturing through drug product, sterile fill/finish, packaging, and commercial supply. Operates 31+ FDA-registered facilities globally. 158 FDA inspections on record (52 NAI, 104 VAI, 2 OAI). Also provides cell therapy manufacturing solutions (CTS Rotea cell processing system), laboratory informatics, bioprocessing equipment, and reagents. 4 FDA-approved drug products. Revenue >$40B (full company).

VintaBio

United States

VintaBio is a US-based viral vector CDMO that recently emerged from stealth, specializing in simplified viral vector manufacturing for gene therapies. The company claims 60% reduction in process time, 30% reduction in raw material costs, 5x increase in high-purity vector production, and 90% full capsids through its proprietary VintaProcess technology. Team has 120+ years of combined cell and gene therapy experience. Recently opened a custom-built manufacturing facility in Philadelphia.

Viralgen

Spain

Viralgen is a premier CDMO specializing exclusively in AAV-based gene therapy manufacturing, founded in 2017 as a subsidiary of AskBio within the Bayer AG group. Claims the world's largest manufacturing capacity dedicated to AAV. Operates from a cGMP facility in San Sebastian, Spain with bioreactors up to 2,000L. Offers end-to-end services from early construct optimization to commercial campaigns. 50+ clients across US, Europe, Asia, and Australia. 10+ years of lentiviral/AAV experience. 200+ batches in bioreactor. 130+ employees. 7 dedicated cleanrooms. Proprietary TESSA technology platform (from AskBio).

ViroCell Biologics

United Kingdom

ViroCell Biologics is a UK-based CDMO specializing exclusively in the design, optimization, and GMP manufacturing of lentiviral and retroviral vectors for clinical trials. Described as the UK's first clinical trial-focused viral vector manufacturer. Operating from a facility at Great Ormond Street Hospital in London, the company focuses on innovation-driven viral vector design, de-risking, and delivery. The facility reportedly more than doubles Britain's viral vector manufacturing capacity.

Waisman Biomanufacturing

United States

Waisman Biomanufacturing is an academic CDMO based at the Waisman Center at the University of Wisconsin-Madison, specializing in advancing novel biologics and vaccines into early clinical trials. The facility manufactures plasmid DNA, recombinant proteins, cell therapeutics, extracellular vesicle/secretome products, live biotherapeutic products, and viral vectors under cGMP conditions.

WuXi Biologics

China

WuXi Biologics is a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) for biologics, with over 12,000 employees across the US, Ireland, Germany, China, and Singapore. The company provides end-to-end solutions from discovery through commercial manufacturing for biologics including monoclonal antibodies, bispecifics, ADCs, vaccines, and mRNA products using both mammalian and microbial expression systems.

Yposkesi (an SK pharmteco company)

France

Yposkesi, an SK pharmteco company, is one of Europe's largest Contract Development and Manufacturing Organizations (CDMO) for gene therapy viral vector manufacturing. Based near Paris (Evry-Courcouronnes), the company provides end-to-end gene therapy CDMO services including process development, cGMP manufacturing, analytical testing, and regulatory support for AAV, lentivirus, and other viral vectors.

Akron Biotech

United States

Akron Biotech is a leading contract manufacturing organization (CMO/CDMO) providing cGMP-compliant solutions for cell and gene therapy. The company manufactures cytokines, growth factors, media, buffers, and transfection/transduction reagents, and recently expanded to a second 60,000 sq ft biologics manufacturing facility in Sarasota, Florida, to support growing demand for ancillary materials in cell and gene therapy.

Aldevron

United States

Aldevron is a US-based CDMO specializing in manufacturing plasmid DNA, mRNA, and related products for gene therapy, cell therapy, gene editing, and RNA vaccines/therapeutics. The company offers custom and catalog products from research grade through cGMP, with capabilities including mRNA production with LNP encapsulation and fill/finish, supporting discovery through commercialization.

Andelyn Biosciences

United States

Andelyn Biosciences is a gene therapy and viral vector CDMO with deep expertise in the development and production of viral vectors. The company has produced 450+ cGMP clinical batches, supported 75+ INDs, and operates 225,000+ sq ft of facility space. Andelyn offers viral vector manufacturing, plasmid manufacturing, process development, and laboratory services, with a proprietary AAV Curator platform.

Anemocyte S.r.l.

Italy

Anemocyte is an Italian biotech manufacturing organization (self-described as a BMO) specializing in plasmid DNA, mRNA, and viral vector development and manufacturing for the cell and gene therapy sector. They provide GMP-grade contract manufacturing services for advanced therapies.

CATUG (CATUG Biotech)

China

CATUG Biotech (also known as CATUG Biotechnology) is a Chinese CRDMO specializing in plasmid DNA, mRNA, and delivery system manufacturing for cell and gene therapy and nucleic acid therapeutics. The company operates a one-stop service platform covering plasmid CDMO, mRNA CDMO, and delivery system CDMO services, including GMP manufacturing, sterile filling, and analytical/quality study services. CATUG provides end-to-end support from research customization through CMC to technology transfer and GMP production.

Cellab CDMO

Andorra

Cellab CDMO is a Contract Development and Manufacturing Organization based in Andorra, specializing in Advanced Therapy Medicinal Products (ATMPs) including cell and gene therapies. The company provides end-to-end services from concept and early-stage development through clinical programs and commercialization under GMP. Cellab supports therapy developers with an agile approach to accelerate ATMP development from bench to bedside.

CellEasy

France

Cell-Easy (CellEasy) is a French CDMO specializing in GMP cell therapy manufacturing, supporting academic laboratories, biotechs, and pharma companies through development and clinical programs. The company has manufactured over 1,000 clinical doses in its GMP facility and has handled 15+ cell types including T cells, NK cells, T regs, MSCs, iPSCs, and immortalized cell lines across 50+ development programs. Cell-Easy follows ICH Q2(R1), European Pharmacopoeia, EMA/MHRA, and US Pharmacopoeia standards.

Cellex Cell Professionals GmbH

Germany

Cellex Cell Professionals GmbH is a European CDMO with over 10 years of experience in autologous and allogeneic cell therapy, partnering with top pharma companies, biotech firms, and academic institutions for clinical trials and post-approval commercial production. Three approved CAR-T therapies are produced in Cellex's GMP-compliant facilities. The company provides full-service capabilities including cell collection, manufacturing of ATMPs/CGT products, process development and validation, supply chain management, GMP audits of medical facilities, and consulting from preclinical development to commercialization.

CELLforCURE by SEQENS

France

CELLforCURE by SEQENS is a leading EMA-authorized CDMO dedicated to the development and commercial manufacturing of cell and gene therapies (ATMPs). Located near Paris, the company operates a 10,000 m2 site with 3,000 m2 of GMP area featuring 7 independent GMP manufacturing lines, 48 cleanrooms, and an 800 m2 dedicated QC lab. With over 15 years of track record, CELLforCURE has completed 25+ tech transfers, manufactured 600+ autologous CAR-T commercial doses and 10,000+ allogeneic CAR-T clinical vials.

Cellin Technologies

Estonia

Cellin Technologies is an Estonia-based biotechnology company specializing in contract GMP manufacturing of cell therapy products. The company operates a state-of-the-art GMP cleanroom facility for the production of cell therapy medicinal products, adhering to EU GMP regulations. Note: the domain cellintech.com is now parked for sale; the operating company appears under a different web presence.

Cellipont Bioservices

United States

Cellipont Bioservices is a leading cell therapy CDMO based in The Woodlands, Texas, offering tailored development, analytics, and cGMP manufacturing services. The company operates a purpose-built 76,000 sq ft cGMP manufacturing facility inaugurated in 2024, specializing in CAR-T cell therapy development and manufacturing. Cellipont partners with biotech companies to advance cell therapies from process development through commercial manufacturing.

Cellistic

Belgium

Cellistic is a Belgium-based CDMO specializing in iPSC-based cell therapy manufacturing, positioned as a global leader in allogeneic iPSC-derived cell therapy production. The company offers full-spectrum manufacturing services including cell line development, process development, GMP manufacturing platforms, ready-to-use iPSC lines, and proprietary gene-editing capabilities. Cellistic operates Europe's first facility dedicated exclusively to iPSC-based cell therapy development and manufacturing in Mont-Saint-Guibert, Belgium.

CellReady

United States

CellReady is the world's first and only G-Rex centric contract development and manufacturing organization (CDMO), specializing in G-Rex based cell and gene-modified cell therapy development and manufacturing. The company is part of the ScaleReady joint venture (with Bio-Techne and Wilson Wolf) and focuses on cancer cell therapies. CellReady is FDA-registered for manufacturing and acquired cell manufacturing assets from Marker Therapeutics for approximately $19 million.

Center for Breakthrough Medicines (CBM)

United States

Center for Breakthrough Medicines (CBM) is a cell and gene therapy CDMO based in King of Prussia, Pennsylvania, operating at The Discovery Labs campus. CBM offers comprehensive services including plasmid manufacturing (Precision Plasmids), viral vector manufacturing (Genesis Vector Manufacturing Solutions), cell therapy manufacturing, and analytical testing (Analytical Accelerator for AAV testing). SK Pharmteco acquired controlling interest in CBM, and the company has capacity to manufacture therapies for 10,000+ patients.

Centre c3i

Canada

C3i Center Inc is the first CDMO in Canada to receive approval for a Drug Establishment License to commercially produce cell therapy drug products. Based in Montreal, the company provides tailored cell and gene therapy CDMO services from development through commercial manufacturing.

Cognate BioServices

United States

Cognate BioServices was a premier commercial-ready global CDMO specializing in cell and gene therapy manufacturing, acquired by Charles River Laboratories in 2021 for approximately $875 million. The company, along with its gene therapy division Cobra Biologics, provided cell therapy manufacturing, plasmid DNA production, and viral vector capabilities across US and European facilities. It is now integrated into Charles River's cell and gene therapy CDMO solutions.

CoJourney Inc

China

CoJourney Inc is a CDMO partner specializing in cGMP manufacturing for gene therapies, featuring its proprietary Zero Chrom plasmid manufacturing platform that eliminates chromatography for higher purity and lower cost. The company provides plasmid DNA, viral vector (AAV, lentivirus, adenovirus), sgRNA GMP manufacturing, and exosome manufacturing services, having served over 100 customers and delivered more than 400 batches with a proven IND approval track record with FDA and CDE.

Cook MyoSite

United States

Cook MyoSite, Inc. is a subsidiary of Cook Group established in 2002, specializing in muscle-derived cell therapy manufacturing and contract services. The company has over 20 years of GMP manufacturing expertise in autologous muscle-derived cell (AMDC) technologies, with its lead product iltamiocel under FDA RMAT designation for female stress urinary incontinence. Cook MyoSite also provides contract manufacturing services to partners such as Lipella Pharmaceuticals and Imagine Pharma for cell-based therapeutic products.

Creative Biolabs

United States

Creative Biolabs is a US-based ISO 9001:2015 certified CDMO providing comprehensive biotechnology and pharmaceutical services including antibody discovery, viral vector CDMO solutions, CAR-T cell therapy manufacturing, and custom bio-manufacturing. The company offers end-to-end services from discovery through cGMP production for biologics including AAV, lentivirus, adenovirus, and HSV vectors.

ENABLE Biotech Ltd (Switzerland)

Switzerland

ENABLE Biotech is a Swiss CDMO specializing in cell and gene therapy manufacturing for clinical-stage companies. The company operates from a SwissMedic-accredited GMP facility with Grade C production rooms equipped with Grade A isolators, focusing on phase-appropriate CMC expertise at attractive pricing for first-in-human production.

ENCell Co., Ltd.

South Korea

ENCell Co., Ltd. is a South Korean biotechnology company and CDMO specializing in cell and gene therapy, founded in 2018 as a spin-off from Samsung Medical Center. The company operates three separate GMP facilities and provides end-to-end pharmaceutical development services from R&D to regulatory approval, including drug substance/product manufacturing and contract quality testing.

Excellos

United States

Excellos is a San Diego-based cell therapy CDMO spun out of the San Diego Blood Bank, specializing in cGMP manufacturing of adoptive cell therapies including TIL, CAR-T/NK, and TCR therapies. The company provides end-to-end services from donor sourcing and cell characterization through process development and commercial GMP manufacturing in ISO 7 cleanrooms.

FinVector

Finland

FinVector is a Finnish cGMP manufacturer of viral-based gene therapy products with over 30 years of experience in drug discovery science and manufacturing. Its new 25,000 square meter Finport facility in Kuopio, opened in partnership with Ferring Pharmaceuticals, represents one of the world's largest viral vector manufacturing capacities using the iCELLis platform from Pall Corporation.

Fisher BioServices (Thermo Fisher)

Netherlands

Fisher BioServices is part of Thermo Fisher Scientific's Patheon pharma services division, one of the world's largest CDMOs offering end-to-end 360-degree CDMO and CRO solutions. The Patheon platform covers drug substance and drug product manufacturing for small molecules, large molecules, and advanced therapies, along with clinical supply and commercialization services.

Forge Biologics (Ajinomoto Group)

United States

Forge Biologics, acquired by Ajinomoto Group in 2023 for $554-620 million, is a gene therapy CDMO specializing in high-purity adeno-associated virus (AAV) vector and plasmid manufacturing. The company operates a 200,000 sq ft Hearth facility in Columbus, Ohio with 20 cGMP suites and 20,000L bioreactor capacity, providing end-to-end services from preclinical process development through commercial manufacturing.

Fraunhofer Institute for Cell Therapy and Immunology (IZI)

Germany

The Fraunhofer Institute for Cell Therapy and Immunology (IZI) in Leipzig is a contract research and GMP manufacturing institute specializing in cell and gene therapy, vaccines, and biologics. The institute provides GMP-compliant manufacturing of clinical trial materials (ATMPs and biologicals), process development for pharmaceutical manufacturing, and regulatory support for manufacturing authorizations and approvals.